Trials / Recruiting
RecruitingNCT04217018
MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
MR Based Prediction of Molecular Biomarkers or Subgroups in Primary Glioma Using Deep Learning or Machine Learning
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,000 (estimated)
- Sponsor
- The First Affiliated Hospital of Zhengzhou University · Academic / Other
- Sex
- All
- Age
- 1 Year – 95 Years
- Healthy volunteers
- Accepted
Summary
This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new MR sequences (T1, T1c, T2, FLAIR, ADC, DTI, PWI, etc) of patients with primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine algorithms that able to predict molecular pathology or subgroups of gliomas.
Detailed description
Non-invasive and precise prediction for molecular biomarkers such as 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations is challenging. With the development of artificial intelligence, much more potential lies in the preoperative conventional/advanced MR imaging (T1 weighted imaging, T2 weighted imaging, FLAIR, contrast-enhanced T1 weighted imaging, diffusion-weighted imaging, and perfusion imaging) could be excavated to aid prediction of molecular pathology of gliomas. The creation of a registry for primary glioma with detailed molecular pathology, radiological data and with sufficient sample size for deep learning (\>1000) provide considerable opportunities for personalized prediction of molecular pathology with non-invasiveness and precision.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Prediction of molecular pathology | Prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2027-01-01
- Completion
- 2027-06-01
- First posted
- 2020-01-03
- Last updated
- 2021-02-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04217018. Inclusion in this directory is not an endorsement.